Alto Neuroscience Inc (ANRO)

$16.16 +0.35 (2.21%)
Market Cap 480.90M
Revenue (ttm) 0.00
Net Income (ttm) -61.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.18
Volume 150,600
Avg Vol 301,730
Day's Range N/A - N/A
Shares Out 31.07M
Stochastic %K 48%
Beta 2.78
Analysts Strong Sell
Price Target $31.12

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 200 0412
Address:
650 Castro Street, Suite 450, Mountain View, United States
S_Franconi
S_Franconi Feb. 3 at 3:00 PM
$ANRO Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment https://investors.altoneuroscience.com/news/default.aspx
1 · Reply
Ccperk
Ccperk Jan. 22 at 3:23 PM
$ANRO HC reiterated their $50 buy rating yesterday….
0 · Reply
S_Franconi
S_Franconi Jan. 15 at 3:53 AM
$ANRO Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression https://investors.altoneuroscience.com/news/news-details/2026/Alto-Neuroscience-Strengthens-Intellectual-Property-Portfolio-with-Issuance-of-New-Method-of-Treatment-Patent-for-ALTO-207-in-Depression/default.aspx
0 · Reply
prismmarketview
prismmarketview Jan. 14 at 3:22 PM
Alto Neuroscience (NYSE: $ANRO) has secured a new U.S. patent for using its ALTO‑207 combo of pramipexole and ondansetron to treat depression, extending IP protection into the mid‑2040s. https://prismmarketview.com/alto-neuroscience-adds-new-alto-207-patent-in-depression/
0 · Reply
StreetwiseReports
StreetwiseReports Jan. 7 at 8:20 PM
How Do Analysts Rate This Biopharma Targeting Psychiatric Disorders https://ow.ly/oOAy50XT9pq Alto Neuroscience Inc. ($ANRO:NYSE) is developing drug candidates for psychiatric and neurological disorders, utilizing a precision approach rather than a one-size-fits-all method. Read to find out how analysts rate this company.
0 · Reply
signaljumper
signaljumper Jan. 7 at 6:52 AM
$TCRX new stockreport is out last performance from reports $ANRO up over 200% $GLSI 150%, $MLTX over 60% checkout the new report: https://www.patreon.com/posts/tcrx-tscan-inc-147617133?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link
1 · Reply
Ccperk
Ccperk Jan. 6 at 4:00 PM
$ANRO I’m not selling yet….top line data is due Q1 2026 for their fast tracked product Alto-101, using their innovative biomarker strategy. This will be a HUGE milestone imho. I think there is some hedging going on from that purchase agreement last Oct.
1 · Reply
rick_b
rick_b Jan. 6 at 3:39 PM
$ANRO Somebody knows something. 10:33am 1/6/26
0 · Reply
Tstockwizard
Tstockwizard Jan. 3 at 6:04 PM
$ANRO
0 · Reply
rpc630
rpc630 Dec. 30 at 3:32 PM
$SLS $ANRO $OTLK $TEAD AGREED 👍 🤝 👌
0 · Reply
Latest News on ANRO
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Feb 3, 2026, 8:27 AM EST - 17 hours ago

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Jan 14, 2026, 7:27 AM EST - 20 days ago

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

Jan 13, 2026, 8:00 AM EST - 21 days ago

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Dec 3, 2025, 4:05 PM EST - 2 months ago

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026

Nov 28, 2025, 12:38 PM EST - 2 months ago

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:57 AM EST - 2 months ago

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience to Participate in Upcoming Investor Conferences

Oct 28, 2025, 7:34 AM EDT - 3 months ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Announces $50 Million Private Placement Financing

Oct 20, 2025, 7:03 AM EDT - 3 months ago

Alto Neuroscience Announces $50 Million Private Placement Financing

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Oct 20, 2025, 7:01 AM EDT - 3 months ago

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 8, 2025, 9:56 AM EDT - 4 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 10:51 AM EDT - 4 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Oct 3, 2025, 7:34 AM EDT - 4 months ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Sep 13, 2025, 11:50 AM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Sep 9, 2025, 7:09 AM EDT - 5 months ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 28, 2025, 5:40 PM EDT - 5 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 22, 2025, 10:15 AM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 18, 2025, 9:45 AM EDT - 6 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Aug 18, 2025, 8:45 AM EDT - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 4:10 PM EDT - 6 months ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 13, 2025, 8:03 AM EDT - 6 months ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

Aug 4, 2025, 2:46 PM EDT - 6 months ago

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jul 22, 2025, 6:25 PM EDT - 7 months ago

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Jun 30, 2025, 8:03 AM EDT - 7 months ago

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Jun 26, 2025, 7:33 AM EDT - 7 months ago

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Jun 3, 2025, 6:03 AM EDT - 8 months ago

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 29, 2025, 8:03 AM EDT - 8 months ago

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 4:10 PM EDT - 9 months ago

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Apr 28, 2025, 8:03 AM EDT - 10 months ago

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Apr 22, 2025, 8:03 AM EDT - 10 months ago

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 4:10 PM EDT - 11 months ago

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

S_Franconi
S_Franconi Feb. 3 at 3:00 PM
$ANRO Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment https://investors.altoneuroscience.com/news/default.aspx
1 · Reply
Ccperk
Ccperk Jan. 22 at 3:23 PM
$ANRO HC reiterated their $50 buy rating yesterday….
0 · Reply
S_Franconi
S_Franconi Jan. 15 at 3:53 AM
$ANRO Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression https://investors.altoneuroscience.com/news/news-details/2026/Alto-Neuroscience-Strengthens-Intellectual-Property-Portfolio-with-Issuance-of-New-Method-of-Treatment-Patent-for-ALTO-207-in-Depression/default.aspx
0 · Reply
prismmarketview
prismmarketview Jan. 14 at 3:22 PM
Alto Neuroscience (NYSE: $ANRO) has secured a new U.S. patent for using its ALTO‑207 combo of pramipexole and ondansetron to treat depression, extending IP protection into the mid‑2040s. https://prismmarketview.com/alto-neuroscience-adds-new-alto-207-patent-in-depression/
0 · Reply
StreetwiseReports
StreetwiseReports Jan. 7 at 8:20 PM
How Do Analysts Rate This Biopharma Targeting Psychiatric Disorders https://ow.ly/oOAy50XT9pq Alto Neuroscience Inc. ($ANRO:NYSE) is developing drug candidates for psychiatric and neurological disorders, utilizing a precision approach rather than a one-size-fits-all method. Read to find out how analysts rate this company.
0 · Reply
signaljumper
signaljumper Jan. 7 at 6:52 AM
$TCRX new stockreport is out last performance from reports $ANRO up over 200% $GLSI 150%, $MLTX over 60% checkout the new report: https://www.patreon.com/posts/tcrx-tscan-inc-147617133?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link
1 · Reply
Ccperk
Ccperk Jan. 6 at 4:00 PM
$ANRO I’m not selling yet….top line data is due Q1 2026 for their fast tracked product Alto-101, using their innovative biomarker strategy. This will be a HUGE milestone imho. I think there is some hedging going on from that purchase agreement last Oct.
1 · Reply
rick_b
rick_b Jan. 6 at 3:39 PM
$ANRO Somebody knows something. 10:33am 1/6/26
0 · Reply
Tstockwizard
Tstockwizard Jan. 3 at 6:04 PM
$ANRO
0 · Reply
rpc630
rpc630 Dec. 30 at 3:32 PM
$SLS $ANRO $OTLK $TEAD AGREED 👍 🤝 👌
0 · Reply
Ccperk
Ccperk Dec. 26 at 5:55 PM
$ANRO looks like a bunch of bot trading taking place right now. Whoopee 🙄
0 · Reply
ALRAE
ALRAE Dec. 24 at 1:57 AM
$ANRO
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 22 at 7:09 PM
$ANRO hang on longs *
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 22 at 7:07 PM
$ANRO 20.64 turning it on
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 22 at 6:00 PM
$ANRO ive been quite generous with u for a long follower that was financially harmed by me in the past
3 · Reply
Ccperk
Ccperk Dec. 22 at 2:17 PM
$ANRO $35 range added to July 2026 options chain
1 · Reply
Freixetes
Freixetes Dec. 19 at 3:49 PM
$ANRO guys, What we could expect in the next 2/3 weeks? 25/30?
0 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Dec. 18 at 9:23 PM
$ANRO Easiest call of the year. $SLS And $CING on deck. Congrats to all my longs here.
1 · Reply
Ccperk
Ccperk Dec. 18 at 5:36 PM
$ANRO crazy thing is they are pretty much just back to their IPO. Insanely awesome.
0 · Reply
signaljumper
signaljumper Dec. 18 at 5:13 PM
$ANRO 200% so far i called this Stock at my Blog the Reports are all free Update will follow at the Weekend. sign Up for free To get free Stock Reports and chartings https://www.patreon.com/posts/140493447?utm_campaign=postshare_creator&utm_content=android_share
0 · Reply
S_Franconi
S_Franconi Dec. 18 at 4:05 PM
$ANRO Very Bullish.
0 · Reply